DX126-262

N/A

Report date: 2025/02/13 16:05:16

Base Information

Drug NameDX126-262
Drug Alias NameRecombinant anti-HER2 antibody-Tub114重组人源化抗Her2单抗-Tub114偶联剂Recombinant Humanized Anti-Her2 Monoclonal Antibody -Tub114 Conjugate for Intravenous InjectionDAC-001DX126-262
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Disulfide bond linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Tub114 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsTubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHangzhou Dac Biotech Company Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHangzhou Dac Biotech Company Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A